Claims

1. Injection solution, comprising an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent and a pharmaceutical active ingredient which is non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, wherein the content of the pharmaceutical active ingredient is from 8 to 25 % by weight of the copolymer solution, wherein the pharmaceutical active ingredient is selected from the group of Etravirine, Rilpivirine, Doravirine and Dolutegravir.

2. Injection solution according to Claim 1 , wherein the organic solvent is selected from the group of N-methyl-2-pyrrolidone, ethanol, propylene glycol, 2-pyrrolidone, acetone, methyl acetate, ethyl acetate, methyl ethyl ketone, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, caprolactam, decylmethylsulfoxide, a fatty acid and 1-dodecylazacycloheptan-2-one and any combinations or mixtures thereof.

3. Injection solution according to Claim 1 or 2, wherein the copolymer is a poly(lactide-co-glycolide) with a molar ratio of lactide : glycolide from 80 : 20 to 40 : 60.

4. Injection solution according to any one of Claims 1 to 3, where the pharmaceutical active ingredient is Rilpiverine and after contact with water the IR spectrum shows a shift of the 1568 cm^{-1} vibration band of pure Rilpiverine to a vibration band between 1572 and 1576 cm^{-1} or the 1593 cm^{-1} vibration band vanishes.

5. Injection dispersion comprising the injection solution according to any of Claims 1 to 4 as continuous phase and a further pharmaceutical active ingredient which is dispersed therein.

6. Injection dispersion according to Claim 5, wherein the further pharmaceutical active ingredient is a further non-nucleoside reverse transcriptase inhibitor, a nucleoside reverse transcriptase inhibitor or an integrase inhibitor.

7. A process for preparing the injection solution according to any of Claims 1 to 4 by combining the organic solvent in sterile form, the pharmaceutical active ingredient in sterile form and the copolymer in sterile form in a sterile injection device.

8. Kit of parts comprising the organic solvent, the pharmaceutical active ingredient and the copolymer according to any one of Claims 1 to 4 in sterile form, where the pharmaceutical active ingredient and the copolymer are present in dry form in a sterile injection device and the organic solvent is kept separately and can be added into the injection device subsequently.

9. Injection solution according to any of Claims 1 to 4 for use as a pharmaceutical dosage form or for use in preparing a pharmaceutical dosage form for the treatment of HIV.

10. Pharmaceutical dosage form, comprising the injection solution according to any one of Claims 1 to 4 or the injection dispersion according to Claims 5 or 6.

11. Pharmaceutical dosage according to Claim 10, which is a kit of parts, which comprises the injection solution, at least one nucleoside reverse transcriptase inhibitor (NRTI), at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) optionally with a booster, which is a liver enzyme inhibitor.